Polymorphs of azabicyclohexane
The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.
1. A pharmaceutical composition comprising polymorph form A of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane hydrochloride substantially free of other geometric and optical isomers and polymorphic forms thereof and an inert pharmaceutically acceptable carrier or diluent.
2. The pharmaceutical composition of claim 1 in oral unit dosage form.
3. The oral unit dosage form of claim 2 wherein said polymorph form A in crystalline form is present in said oral unit dosage form in the amount of about 25 mg to about 300 mg.
4. The oral unit dosage form of claim 3 wherein said oral unit dosage form is a tablet or capsule.
5. A pharmaceutical composition comprising polymorph form B of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane hydrochloride substantially free of other geometric and optical isomers and polymorphic forms thereof and an inert pharmaceutically acceptable carrier or diluent.
6. The pharmaceutical composition of claim 5 in oral unit dosage form.
7. The oral unit dosage form of claim 6 wherein said polymorph form B in crystalline form is present in said oral unit dosage form in the amount of about 25 mg to about 300 mg.
8. The oral unit dosage form of claim 7 wherein said oral unit dosage form is a tablet or capsule.
9. A pharmaceutical composition comprising polymorph form C of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane hydrochloride substantially free of other geometric and optical isomers and polymorphic forms thereof and an inert pharmaceutically acceptable carrier or diluent.
10. The pharmaceutical composition of claim 9 in oral unit dosage form.
11. The oral unit dosage form of claim 10 wherein said polymorph form C in crystalline form is present in said oral unit dosage form in the amount of about 25 mg to about 300 mg.
12. The oral unit dosage form of claim 11 wherein said oral unit dosage form is a tablet or capsule.
13. A pharmaceutical composition comprising a mixture of polymorph form A and either or both polymorph form B and polymorph form C of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo [3.1.0]hexane hydrochloride wherein the amount of polymorph form A ranges from about 85% to about 95% (by weight).
14. A pharmaceutical composition comprising a mixture of polymorph form A and either or both polymorph form B and polymorph form C (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo [3.1.0]hexane hydrochloride wherein the amount of polymorph form A ranges from about 95% to about 99% (by weight).
15. A pharmaceutical composition comprising a mixture of polymorph form C and either or both polymorph form A and polymorph form B of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo [3.1.0] hexane hydrochloride.
16. The pharmaceutical composition of claim 1 wherein said pharmaceutical composition comprises about 50 mg to about 1000 mg of said polymorph.